- Home
- S vs MDGL Comparison
S vs MDGL Comparison
Compare S & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- S
- MDGL
- Stock Information
- Founded
- S 2013
- MDGL 2011
- Country
- S United States
- MDGL United States
- Employees
- S N/A
- MDGL N/A
- Industry
- S EDP Services
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- S Technology
- MDGL Health Care
- Exchange
- S Nasdaq
- MDGL Nasdaq
- Market Cap
- S 8.7B
- MDGL 7.4B
- IPO Year
- S 2021
- MDGL N/A
- Fundamental
- Price
- S $23.62
- MDGL $308.45
- Analyst Decision
- S Buy
- MDGL Buy
- Analyst Count
- S 26
- MDGL 14
- Target Price
- S $29.35
- MDGL $347.33
- AVG Volume (30 Days)
- S 6.0M
- MDGL 319.4K
- Earning Date
- S 12-04-2024
- MDGL 10-31-2024
- Dividend Yield
- S N/A
- MDGL N/A
- EPS Growth
- S N/A
- MDGL N/A
- EPS
- S N/A
- MDGL N/A
- Revenue
- S $770,115,000.00
- MDGL $76,813,000.00
- Revenue This Year
- S $33.89
- MDGL N/A
- Revenue Next Year
- S $26.25
- MDGL $194.49
- P/E Ratio
- S N/A
- MDGL N/A
- Revenue Growth
- S 34.38
- MDGL N/A
- 52 Week Low
- S $14.33
- MDGL $168.25
- 52 Week High
- S $30.76
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- S 37.39
- MDGL 49.18
- Support Level
- S $23.45
- MDGL $295.02
- Resistance Level
- S $24.22
- MDGL $315.09
- Average True Range (ATR)
- S 1.01
- MDGL 10.62
- MACD
- S -0.34
- MDGL -4.31
- Stochastic Oscillator
- S 9.44
- MDGL 32.63
About S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.